Sandbox Reserved 825: Difference between revisions
| Line 51: | Line 51: | ||
MTOR has been found to form two distinct complexes called '''mTOR complex 1''' ([http://en.wikipedia.org/wiki/MTORC1 mTORC1]) and '''mTOR complex 2''' ([http://en.wikipedia.org/wiki/MTORC2 mTORC2]).<br /> | MTOR has been found to form two distinct complexes called '''mTOR complex 1''' ([http://en.wikipedia.org/wiki/MTORC1 mTORC1]) and '''mTOR complex 2''' ([http://en.wikipedia.org/wiki/MTORC2 mTORC2]).<br /> | ||
While mTORC1 is bound and inhibited by rapamycin mTORC2 is not affected by rapamycin presence. <ref> PMID: 20005306 </ref> | While mTORC1 is bound and inhibited by rapamycin mTORC2 is not affected by rapamycin presence. <ref> PMID: 20005306 </ref> Depending on the formed complex mTOR activity can provoke different cellular responses like activation of translation, inhibition of autophagy (mTORC1). <br /> | ||
Depending on the formed complex mTOR activity can provoke different cellular responses like activation of | |||
inhibition of autophagy (mTORC1). MTORC2 on the other hand regulates the assembly of cytoskeleton and activates the | MTORC2 on the other hand regulates the assembly of cytoskeleton and activates the '''Protein Kinase B''' ([http://en.wikipedia.org/wiki/Protein_Kinase_B Akt]) which plays a central role in the phosphoinositide 3-kinase [http://en.wikipedia.org/wiki/PI3K/AKT/mTOR_pathway pathway] , which leads to cell survival and [http://en.wikipedia.org/wiki/S_phase S-phase] entry and is revealed to be overactive in many human cancers. <ref> PMID: 12040186 </ref><br /> | ||
'''Protein Kinase B''' ([http://en.wikipedia.org/wiki/Protein_Kinase_B Akt]) which plays a central role in the phosphoinositide 3-kinase [http://en.wikipedia.org/wiki/PI3K/AKT/mTOR_pathway pathway] which leads to cell survival and [http://en.wikipedia.org/wiki/S_phase S-phase] entry and is revealed to be overactive in many human cancers. <ref> PMID: 12040186 </ref><br /> | |||
The FRB domain is responsible for the ligand-mediated regulation of mTOR activity. Though the inhibitor rapamycin | The FRB domain is responsible for the ligand-mediated regulation of mTOR activity. Though the inhibitor rapamycin has been successfully used as an immunosuppressant it cannot be used to treat cancer since rapamycin has no effect on mTORC2. <br /> | ||
has been successfully used as an immunosuppressant it cannot be used to treat cancer since rapamycin has no effect on | Therefore scientists are interessted in discovering new binding sites for inhibitors like HTS-1 that inhibit mTORC2 and can help to fight cancer. <ref> PMID: 17684489 </ref> | ||
mTORC2. Therefore scientists are interessted in discovering new binding sites for inhibitors like HTS-1 that inhibit | |||
mTORC2 and can help to fight cancer. <ref> PMID: 17684489 </ref> | |||
== '''References''' == | == '''References''' == | ||